

Pathophysiology of the proatherothrombotic state in the metabolic syndrome

Ivan Palomo¹, Rodrigo Moore-Carrasco¹, Marcelo Alarcon¹, Armando Rojas², Francisco Espana³, Vicente Andres⁴, Herminia Gonzalez-Navarro⁴

¹Research Program of Cardiovascular Disease Risk, Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Chile, ²Biomedical Research Laboratory, School of Medicine, Universidad Catolica del Maule, Chile, ³Research Center, Hospital Universitario La Fe, Valencia, Spain, ⁴Laboratory of Vascular Biology, Department of Molecular and Cellular Pathology and Therapy, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Cientificas, Valencia, Spain

TABLE OF CONTENTS

1. Abstract
2. Pathophysiology of the metabolic syndrome
3. Endothelial dysfunction in the metabolic syndrome
 - 3.1. Evidence of endothelial dysfunction in the metabolic syndrome and underlying mechanisms
 - 3.2. Mouse models of endothelial dysfunction based on nitric oxide synthase-deficiency
4. Alterations in plaque stability, coagulation and fibrinolysis systems in the metabolic syndrome
 - 4.1. Hypercoagulation and hypofibrinolysis states
 - 4.2. Platelet activation
5. Mouse models to study plaque vulnerability and thrombus formation
6. Mouse models of atherothrombosis and metabolic syndrome
7. Conclusions and perspectives
8. Acknowledgements
9. References

1. ABSTRACT

Obesity and insulin resistance are very frequently associated to the metabolic syndrome (MetS), play a pivotal role in the development of type 2 diabetes mellitus (T2DM) and increases the risk of cardiovascular disease. Although it varies among ethnic groups, the worldwide prevalence of MetS is 23% in young adults and increases with age. Remarkably, the prevalence of MetS is expected to rise during the next decades due to the acquisition of unhealthy life-style habits (sedentarism, smoking, unhealthy diet). A major pathological alteration present in the MetS is a prothrombotic state resulting from endothelial dysfunction and hypercoagulability produced by a dysbalance of coagulation factors and proteins regulating fibrinolysis. Although intensive research in recent years has identified a number of prothrombotic alterations in MetS patients, a better understanding of the molecular mechanisms underlying the relationship between MetS and atherothrombosis is required to improve prevention and treatment. In this review we discuss the main alterations in the endothelial function, coagulation cascade, fibrinolysis and platelet function promoting atherothrombosis in MetS and available mouse models exhibiting alterations in atherothrombosis.

2. PATHOPHYSIOLOGY OF THE METABOLIC SYNDROME

MetS is a heterogeneous complex disease that is clinically associated to increased risk of T2DM, atherosclerosis and associated cardiovascular disease (CVD) (e.g., myocardial infarction and stroke). The diagnosis of MetS is based on the presence of at least three factors among glucose intolerance, insulin resistance (IR), visceral abdominal obesity, hypertension, increased triglyceridemia, and decreased plasma levels of high-density lipoprotein (HDL) cholesterol (1). Epidemiological studies based on the National Cholesterol Education Programme criteria have shown that between 20% and 30% of the adult population in industrialized countries are affected by the MetS (2). The condition is progressive, beginning with borderline risk factors that eventually progress to categorical risk factors (3-5). Obesity and IR are very frequently associated to the MetS and play a pivotal role in the development of T2DM, which further increases the incidence of CVD in humans (6). The MetS is becoming one of the most relevant cardiovascular risk factors since its prevalence is expected to increase by 165% in the next 40 years, representing the health plague of the 21st century (7). Population aging and acquisition of

sedentary lifestyle patterns (e.g., obesity and physical inactivity) are major driving forces behind this syndrome.

Dyslipidemia, including plasmatic accumulation of small dense low-density lipoprotein (LDL) particles, triglycerides, and apolipoprotein B (apoB), and low level of HDL, and dysglycemia (glucose intolerance and elevated fasting glucose) are among the metabolic abnormalities found in MetS subjects. Individuals with the MetS are also characterized by a prothrombotic state (increased coagulability and reduced fibrinolytic activity), as well as a proinflammatory state that increases plaque instability and favors formation and persistence of thrombus (Figure 1). Endothelial dysfunction and platelet reactivity are considered key determinants of the proatherothrombotic state in the MetS (8-10). On the other hand, abdominal visceral obesity and IR are two of the predominant risk factors behind the MetS (3). The adipose tissue has emerged as an active endocrine and paracrine organ which secretes adipokines, such as adiponectin, leptin, resistin and proinflammatory mediators like tumor necrosis factor alpha (TNF- α), interleukin-1 (IL-1) and IL-6, and plasminogen activator inhibitor-1 (PAI-1). These molecules have profound effects on several physiological functions including carbohydrate and lipid metabolism, endothelial function, vascular homeostasis and inflammatory processes (11, 12). Other coagulation factors, like tissue factor (TF), are upregulated in the MetS due to the stimulation of proinflammatory cytokines and other endothelial mediators enhancing CVD risk and favoring thrombus formation following plaque rupture (13). Cellular and epidemiological studies have also linked IR with endothelial dysfunction, possibly as a consequence of glucotoxicity, lipotoxicity and inflammatory processes which characterize the MetS (14).

This review discusses the pathophysiology of the prothrombotic state associated to MetS, covering aspects of endothelial dysfunction, alterations of coagulation/fibrinolysis cascade, platelet activation and existing murine models of atherothrombosis and MetS.

3. ENDOTHELIAL DYSFUNCTION IN THE METABOLIC SYNDROME

3.1. Evidence of endothelial dysfunction in the metabolic syndrome and underlying mechanisms

The endothelium, which functions as a physical barrier between blood and the vascular wall, is a strategically located organ with several endocrine and paracrine functions. Under physiological conditions, the endothelium releases vasoactive substances which inhibit vascular constriction, leukocyte adhesion, vascular smooth muscle cell (VSMC) growth and platelet aggregation (15-17). Besides its function as a regulator of vascular tone, the endothelium plays an important role in the maintenance of vascular homeostasis due to its antiinflammatory and antiatherogenic properties (16, 17). Indeed, a common feature of IR states, MetS and atherothrombosis is the establishment of endothelial dysfunction characterized by a deficiency of nitric oxide (NO) production in response to physiological stimuli, increased expression of adhesion

molecules on the endothelial cell (EC) surface, and inflammatory changes that underlie early processes of atherosclerosis and CVD (18). Decreased NO bioavailability in IR states leads to vasoconstriction and leukocyte activation, promotes thrombosis and VSMC proliferation, and is linked to hypertension, hypercholesterolemia, atherosclerosis and aging, thus contributing to the development of CVD (19).

A variety of humoral substances that alter endothelial function, including free fatty acids, adipokines and prooxidant molecules such as oxidized LDL (oxLDL), have been identified in the MetS. These mediators activate signaling kinases and are also closely linked to the endothelial production of reactive oxygen species, a hallmark in the inflammatory milieu that contributes to endothelial dysfunction and atherogenesis in MetS and T2DM patients (20-23). Multiple mechanisms have been implicated in the development of endothelial dysfunction in the setting of IR, such as inflammation and vascular production of the reactive oxygen species superoxide and peroxynitrite, which scavenge free NO reducing its bioavailability and promote EC apoptosis (24-31). The divergent effects of IR on the insulin signaling pathway may also be a crucial determinant of endothelial dysfunction. The sequential phosphorylation of the insulin receptor (INSR), insulin receptor substrates (IRS), PI-3 kinase and Akt constitute a common pathway by which insulin stimulates glucose uptake in metabolically active cells and promotes NO production by ECs (14). However, this pathway has been shown to be selectively down-regulated by IR in animals and humans leading to a reduction in NO production (32, 33).

Hyperglycemia is another common trait of the MetS that has a significant impact on endothelial function, particularly on vessel relaxation, through a mechanism involving advanced glycation end-products (AGEs). Targets of AGEs are the endothelium-derived relaxing factors NO and prostacyclin (PGI₂). On the other hand, glycated serum albumin decreases *in vitro* the production of PGI₂ by microvascular ECs (34) and induces the production of the potent vasoconstrictor endothelin-1 through nuclear factor-kappaB activation (35). The accumulation of AGEs in the extracellular matrix might result in NO depletion (36). In addition, a marked reduction in protein and mRNA levels of endothelial nitric synthase (NOS) occurs as a result of decreased serine phosphorylation of this enzyme and increased rate of mRNA degradation (37-39).

The increased risk of CVD in patients with MetS has been partially attributed to the inflammatory state provoked by visceral obesity (Figure 1). For example, endothelial dysfunction in MetS patients has been related to the secretion by visceral adipose tissue of proinflammatory and proatherosclerotic adipokines, including TNF- α , leptin, IL-6, and angiotensinogen (40). TNF- α contributes to IR by inhibiting insulin signaling. Leptin activates the immune system and increases blood pressure. IL-6 stimulates in obese subjects the hepatic production of C-reactive protein (CRP), an acute inflammatory protein.




Figure 1. Pro-atherothrombotic state in metabolic syndrome. This figure illustrates mechanisms by which the MetS induces endothelial dysfunction and the underlying inflammatory response. Platelet adhesion to ECs occurs through interactions between ligands and their receptor (e.g., PSGL-1/P-selectin, GPIb/FVW, integrins), which in turn mediates the release of bioactive molecules, either from platelets or ECs, thus further enhancing platelet-monocyte and endothelium-monocyte interactions. Ultimately, increments in both fibrinogen and PAI-1 and plaque rupture can trigger a thrombotic event. PMP: platelet microparticles; MMP: monocyte microparticles.

Angiotensin II (produced from angiotensinogen) exerts its adverse endocrine effects via the angiotensin II type 1 receptor (AT1), leading to oxidative stress, vasoconstriction, aldosterone secretion, renal sodium resorption, vasopressin release, PAI-1 expression and thrombosis (41). In contrast, plasmatic levels of adiponectin, a protein secreted by the adipose tissue into the circulation at relatively high levels in healthy human subjects, are markedly reduced in MetS. Circulating levels of adiponectin correlate negatively with the parameters characteristics of IR (e.g., percent body fat, central fat distribution, fasting plasma insulin, and oral glucose tolerance), and positively with parameters related to glucose intolerance (e.g., glucose disposal during euglycemic insulin clamp) (41). Plasma adiponectin levels are also significantly lower in patients with coronary artery disease compared with control subjects (42, 43). Studies in animal models and human subjects have demonstrated an association between circulating adiponectin levels and endothelial function. Forearm blood flow during reactive

hyperemia in humans is inversely correlated with adiponectin, indicating that this cytokine is closely associated with endothelium-dependent vasodilation (44-46). Moreover, independently of a correlation with insulin sensitivity, circulating adiponectin levels in humans are positively associated with arterial vasodilation in response to nitroglycerine, a measure of endothelium-independent vasodilation (47).

The induction of endothelial dysfunction has also been associated with the presence of dyslipidemia (41). Specifically, circulating free fatty acids, which are characteristic of the dyslipidemia in MetS states, have been shown to have a deleterious effect on endothelial functions (48).

The biochemical abnormalities associated with IR mentioned above, including reduced NO bioavailability, increased production of reactive oxygen species and downregulation of PI-3 kinase-mediated signaling, may

impair vascular repair by endothelial progenitor cells (EPCs) (49, 50), which are blood borne bone marrow-derived cells that contribute to neoangiogenesis induced by tissue ischemia (51-53). It has been suggested that proinflammatory factors associated to the MetS lead to cell damage and impaired regeneration within the vessel wall (54). In addition, the accumulation of cardiovascular risk factors is associated with reduced number and dysfunction of EPCs (55, 56). Therefore, a poor regenerative ability of the vessel wall may contribute to increased risk of atherothrombosis in MetS states.

3.2. Mouse models of endothelial dysfunction based on nitric oxide synthase-deficiency

As discussed in the previous section, reduced bioavailability of NO may contribute to endothelial dysfunction in the MetS. This gas can be produced by neuronal (nNOS, type I), inducible (iNOS, TypeII), and endothelial (eNOS, Type III) NOS (57, 58). These isoforms exhibit complex and overlapping patterns of expression. nNOS is found in neurons in the brain and in the nonadrenergic, noncholinergic, autonomic nervous system. iNOS can be induced in macrophages in response to infection or tumor immunity. eNOS is found in ECs and is the isoform involved in endothelium-dependent relaxation. nNOS and eNOS are constitutively produced and their activity is regulated by intracellular calcium concentrations. In contrast, iNOS is induced by a variety of stimuli such as TNF and interferon.

Studies with genetically-modified mice have helped clarify the role of the three NOS isoforms (59). *nNOS*-knockout mice are resistant to global and focal cerebral ischemia, confirming a role for neuronal NO in cellular toxicity after stroke. In contrast, *eNOS*-knockout mice are more prone to stroke consistent with a protective effect of NO on the brain vasculature. Furthermore, *eNOS*-knockout mice are hypertensive, lack endothelium-dependent relaxing factor activity and respond to vascular injury with increased neointimal proliferation, consistent with a physiological role for NO as a suppressor of VSMC proliferation (59). Finally, *iNOS*-deficient mice exhibit altered immune responses, increased susceptibility to bacterial and viral pathogens and resistance to sepsis-induced hypotension (58).

Interestingly, nephrotic diabetes is a characteristic of mice lacking all three NOS isoforms (*n/i/eNOS*-deficient mice) (60), which also develop severe coronary arteriosclerosis, thrombosis and myocardial infarction (61). Characterization of *n/i/eNOS*-deficient mice demonstrated that they develop a phenotype similar to the MetS in humans, featuring visceral obesity, hypertension, hypertriglyceridemia and impaired glucose tolerance. Remarkably, oral treatment of *n/i/eNOS*-deficient mice with an angiotensin II type 1 receptor blocker significantly reduces both coronary atherosclerosis and the occurrence of myocardial infarction and ameliorates metabolic abnormalities, thus demonstrating that disruption of the NOS system impairs cardiovascular and metabolic homeostasis at least in part through activation of angiotensin II type 1 receptor. The occurrence in *n/i/eNOS*-

deficient mice of acute events along with metabolic abnormalities makes this animal model a suitable tool to study the proatherothrombotic state associated to the MetS.

Additional mouse models have highlighted a link between dysfunction of the endothelial NOS system with the MetS and atherothrombosis. Studies in *Insr*-null mice, which exhibit mild IR and endothelial dysfunction, support a role for endothelial cell superoxide production as a mechanism underlying the early reduction in NO bioavailability (62). It has been also suggested that the toll-like receptor-4, a main receptor of innate immunity, plays a relevant role as a mediator of the deleterious effects of free fatty acids on endothelial NO signaling and on insulin-dependent stimulation of eNOS, thus providing a mechanism by which diet-induced obesity promotes vascular inflammation and IR (63).

4. ALTERATIONS IN PLAQUE STABILITY, COAGULATION AND FIBRINOLYSIS SYSTEMS IN THE METABOLIC SYNDROME

4.1. Hypercoagulation and hypofibrinolysis states

The increased risk of CVD in MetS patients is linked to a hypercoagulable and hypofibrinolytic state (64). In this sense, augmented plasma levels of several factors involved in clotting and fibrinolysis have been associated to the MetS (41, 65-69). For example, MetS and IR patients have increased cardiovascular risk associated to elevated plasma levels of factor VII, fibrinogen, factor XIII B-subunit, factor VIII, von Willebrand factor (vWF) and PAI-1 (70-72). Moreover, IR strongly correlates with factor XIII B-subunit (72).

The superoxide radicals, which accumulate in the MetS, are related to endothelial inflammation and the ensuing activation of monocytes (73). The microparticles (MP) liberated from monocytes during cellular activation or apoptosis can expose anionic phospholipids, P-selectin (CD62P), CD42a and also TF (74, 75), a primary cellular initiator of blood coagulation whose expression in the vasculature promotes thrombosis. TF is expressed at high levels by VSMC and macrophages within atherosclerotic plaques, is upregulated by cytokines favoring thrombus formation after plaque rupture and therefore its activity is associated with an increase in CVD risk in the MetS (13, 76). TF activity is inhibited by various agents, including TF pathway inhibitor (TFPI), whose activity reduces thrombosis in animal models (77, 78). Notably, TFPI activity has been negatively correlated with parameters characteristic of the IR and the MetS (79) as well as body mass index (80). In contrast, factor VII activity positively correlates with both body mass index and triglyceride levels (41) and has been shown to increase during postprandial hyperlipidemia (81). The simultaneous increase in soluble TF and factor VII activates the coagulation protease cascade, thus enhancing the risk of acute events in the MetS by leading to fibrin deposition and activation of platelets (13).

MetS patients exhibit hypofibrinolysis (6, 9, 82). This alteration in fibrinolysis associated to the MetS is

mainly due to an increment in the serum levels of PAI-1, which reflect dysfunction of the fibrinolytic system that can lead to arterial thrombosis and CVD (83-86). In addition, increased levels of PAI-1, which have been found in T2DM patients (87, 88) and strongly correlate with IR, are linked to increased risk of atherothrombosis in humans (87, 89). A number of proinflammatory cytokines characteristic of the MetS, like TNF- α , leptin, IL-6 and angiotensinogen, have been demonstrated to increase the serum levels of PAI-1 due to its overexpression in adipose tissue (90-92). Recent findings also suggest that PAI-1 may be involved in adipose tissue development and may contribute to obesity through indirect effects on insulin signaling, adipocyte differentiation and recruitment of inflammatory cells in adipose tissue (93). In agreement with these studies, healthy diet, weight loss and lifestyle modifications decrease inflammation and the levels of PAI-1 (92, 94-96). Finally, decreased plasma tissue plasminogen activator activity is related to IR in patients with MetS (97) and a positive correlation between insulin levels and the thrombin-activable fibrinolysis inhibitor has been observed (98), thus favoring thrombus persistence. These changes contribute to attenuation of plasminogen conversion, resulting in a hypofibrinolytic state (41).

The reduced level of circulating HDL-cholesterol may also contribute to the prothrombotic phenotype of MetS patients. Indeed, HDL-cholesterol enhances the anticoagulant protein C pathway by stimulating the generation of activated protein C (99) and reduced levels of circulating activated protein C are associated with the extent and severity of coronary atherosclerosis and a higher risk of myocardial infarction, which might be related to the anticoagulant and antiinflammatory properties of anticoagulant protein C (100).

It has been suggested that PAI-1 polymorphisms probably interact with known environmental risk factors (chronic hyperglycaemia, obesity, etc.) to induce a more severe insulin-resistant metabolic profile in overweight subjects, and to further increase risk for coronary heart disease in diabetic patients (101).

4.2. Platelet activation

In thrombotic arterial disease, the increased reactivity of platelets plays a major role in thrombus formation induced by atherosclerotic plaque rupture (102, 103). Subjects with increased platelet reactivity have an increased risk of suffering coronary events and death (104-106). It has been shown that patients with MetS and diabetes exhibit higher degree of platelet activation (64, 107, 108), and markers of platelet activation such as P-selectin (CD62P), CD63, PAC-1 and annexin V are increased in diabetic subjects (109). P-selectin allows the recruitment of leukocytes to areas of inflammation thus favoring the formation of lesions (110). Furthermore, platelets are known to adhere to activated or damaged ECs both *in vitro* (111) and *in vivo* (112, 113). On the other hand, platelets also produce TF (114), a factor which is upregulated in the MetS and promotes thrombosis (13). However, the contribution of platelets to MetS

pathophysiology seems to be more complex as these cells may also contribute to atherosclerotic plaque development (Figure 1).

In addition to the direct role of platelets in arterial thrombus formation, they also contribute to the process through the release of platelet microparticles (PMP), which contain phospholipids with procoagulant function (115, 116). In agreement with this, elevated levels of PMP have been detected in patients with myocardial infarction (117) and diabetes (109, 115). It has been shown that PMP promotes thrombus formation by binding to the subendothelial matrix, which may act as a substrate for further platelet binding in a GPIIb/IIIa-dependent manner (116). PMP may also activate ECs and leukocytes by releasing arachidonic acid and other molecules (118), and also cause or worsen endothelial dysfunction (119).

Other abnormalities of the MetS, including dyslipidemia, enhanced oxidative stress and the generation of biologically active oxidized lipids are associated with a prothrombotic phenotype. Podrez *et al* (120) demonstrated that the interaction of platelet CD36, a major platelet glycoprotein, with specific endogenous oxidized lipids promotes platelet activation and thrombosis. By using multiple murine models of thrombosis, the authors demonstrated that deletion of CD36 protects mice from hyperlipidemia-associated enhanced platelet reactivity and thrombosis.

Other studies have also suggested a role of the circulating activated platelets in atherosclerosis development, which enhances the risk of thrombosis. In this sense, circulating activated platelets have been shown to increase P-selectin (CD62P)-mediated monocyte arrest on the surface of incipient atherosclerotic lesions and exacerbate atherosclerosis, possibly due to the interaction between GPIIb-IIIa expressed by activated platelets and endothelial ICAM-1 (121) as well as to the binding of P-selectin from activated platelets to endothelial P-selectin glycoprotein ligand 1 (PSGL-1) (122).

Activated platelets may also play a role in thrombosis by enhancing a proinflammatory state. Thus, upon activation, platelets release adhesive and proinflammatory molecules from α granules, which cause endothelial dysfunction (123). Platelets store and express CD40L on their surface. Once they are activated, platelets release CD40L which induces endothelial expression of cell adhesion molecules such as E-selectin, ICAM-1 and VCAM (124). Furthermore, the expression of CD40L on the platelet surface favors their adherence to the endothelium and stimulates the release of IL-8 and monocyte chemoattractant protein 1 (MCP-1) from platelets, promoting leukocyte recruitment to incipient lesions (124, 125). Activated platelets also secrete the EC activator IL-1 β , thus promoting the release of IL-6 and IL-8 and expression of cell adhesion molecules (126, 127).

Chemokines produced by platelets also enhance monocyte recruitment. Platelet factor 4 (PF-4) is released in high amounts by activated platelets, promoting

chemotaxis of monocytes and LDL retention by ECs through inhibition of LDL receptor (LDLr) degradation in the endothelium (128). The chemokine RANTES (regulated on activation normal T cell expressed and secreted) secreted by activated platelets is involved in vascular recruitment of monocytes (129). Furthermore, the presence of PF4 enhances the arrest of RANTES-stimulated monocytes and monocytic cells on activated ECs, and binding of PF4 to the surface of monocytes is increased by RANTES (129). Circulating PMPs (see above) can also provoke the release of RANTES, thus favouring atherosclerotic plaque development (130).

Multiple mechanisms contribute to atheroma development, including abnormal VSMC proliferation and migration, two processes that are coordinately regulated by p27 (131-133), a growth suppressor which inhibits murine atherosclerosis (134, 135). Platelet-derived growth factor (PDGF) released during platelet activation also contributes to atherosclerosis by stimulating VSMC proliferation and migration and monocyte recruitment (136).

5. MOUSE MODELS TO STUDY PLAQUE VULNERABILITY AND THROMBUS FORMATION

The initial event in coronary thrombosis is typically provoked by coronary atherosclerotic plaque rupture or plaque ulceration as a consequence of disruption of the fibrous cap that protects the lesion (137). The definition of plaque stability, vulnerability and rupture in animal models is an unresolved issue. Moreover, the mechanisms underlying atherothrombosis are ill defined, in part due to the lack of 'true' models that mimic the disease in humans (137-141). Major progress into the understanding of the molecular mechanisms underlying atherosclerosis has been achieved through the generation and phenotypic characterization of genetically-engineered mice, mainly the apolipoprotein E-deficient (*apoE*^{-/-}) and the LDLr-deficient (*LDLr*^{-/-}) mouse models of atherosclerosis (142). Nonetheless, these murine models do not seem to reliably reproduce the later stages of atherosclerosis in humans, including spontaneous plaque rupture and hemorrhage (143). Recent studies, however, have permitted significant advances in modeling these processes in the mouse. Jackson *et al.* defined plaque rupture in mice as 'a visible defect in the cap accompanied by intrusion of erythrocytes into the plaque below' (144). The existing mouse models of plaque rupture and thrombosis, which are mainly based on the induction of the atheromatous plaque rupture and thrombosis by different means, typically in *apoE*^{-/-} and *LDLr*^{-/-} mice, have been the subject of excellent reviews (e.g.) (138, 140, 143, 145, 146). This section summarizes key findings derived from some of these models.

Mice doubly deficient for *apoE* and the high-density lipoprotein receptor *SR-BI* exhibit features characteristic of human coronary heart disease, including spontaneous multiple myocardial infarction, cardiac dysfunction, and coronary atherosclerotic plaques displaying cholesterol clefts and extensive fibrin

deposition, which indicate the presence of hemorrhage and clotting (147).

The combination of ligation and subsequent cuffing of the carotid artery in *apoE*^{-/-} mice results in disruption of the macrophage-rich neointima, intralésional hemorrhage and thrombosis (148). Likewise, 8 weeks of fat feeding leads to acute plaque rupture in the brachiocephalic artery of male *apoE*^{-/-} mice (149). In this animal model, pravastatin treatment inhibits early plaque rupture and is also effective when begun after unstable plaques have developed (149).

Manipulation of apoptosis (150, 151) and matrix metalloproteinase (MMP) activity in preexisting atherosclerotic lesions (152) have been also shown to provoke plaque rupture and hemorrhage in *apoE*^{-/-} mice. Indeed, induction of atherosclerotic plaque vulnerability and rupture has been reported in this animal model upon adenovirus (Ad)-mediated transfer of the proapoptotic factors p53 (150) and Ad-FasL (151). Treatment with a vasopressor compound increases spontaneous rupture in Ad-p53-transferred mice (150), and thrombotic rupture, intraplaque haemorrhage, buried caps and iron deposits are seen in carotid artery lesions of Ad-FasL-transferred mice (151). By analyzing *apoE*/MMP3, *apoE*/MMP7, *apoE*/MMP9 and *apoE*/MMP12 doubly-deficient mice, Johnson *et al.* (152) provided evidence that different MMPs play divergent roles on atherosclerotic plaque development and stability in brachiocephalic arteries, since MMP-7 has no effect on plaque growth or stability, although it is associated with reduced VSMC neointimal content, MMP-12 supports lesion expansion and destabilization, and MMP-3 and MMP-9 limit plaque growth and promote a stable plaque phenotype (152). However, using a perivascular collar placement model of atherosclerosis, de Nooijer *et al.* (153) reported that lesional overexpression of MMP-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis.

Additional murine models of thrombosis include genetically-manipulated mice with defects in the platelet/coagulation system (138, 146). For example, homozygosity for the Factor V Leiden mutation in *apoE*^{-/-} mice leads to enhanced arterial thrombosis and atherosclerosis (154). Regarding manipulation of the plasminogen system in *apoE*^{-/-} mice, loss of plasminogen greatly accelerates atherosclerotic lesion formation (155), and overexpression of PAI-1, a key regulator of tissue-type plasminogen activator (tPA) which may promote plaque progression by inhibiting fibrinolysis and predispose to ischemic heart disease, leads to enhanced coronary arterial thrombosis (156). However, PAI-1 deficiency results in both detrimental and protective effects on atherosclerotic lesion development. On one hand, Eitzman *et al.* (157) reported prolonged time to occlusive thrombosis following photochemical injury to carotid atherosclerotic plaque in *apoE*/PAI-1 doubly deficient mice compared to *apoE*^{-/-} counterparts. On the other hand, Lutun *et al.* (158) find that loss of PAI-1 in *apoE*^{-/-} mice promotes the growth of advanced atherosclerotic plaques coincident with enhanced

extracellular matrix deposition, collagen fiber disorganization and degradation.

A major role of TF in atherothrombosis has been demonstrated in murine models (13, 159-161). First, thrombosis is markedly reduced in a carotid artery injury model in *TF^{flxed/flxed}SM22 α -Cre* mice harboring VSMC-specific deletion of TF (13). Second, *apoE*^{-/-} mice with only one allele of TFPI inactivated exhibit enhanced TF activity within the atherosclerotic plaque, increased atherosclerosis burden and enhanced thrombosis measured as decreased time to occlusive thrombosis after photochemical carotid plaque injury compared to *apoE*^{-/-} controls (159). CRP has been also implicated in the pathogenesis of arterial thrombosis, since CRP-transgenic mice subjected to two different models of arterial injury show an expedited and higher rate of thrombotic occlusion (160). Moreover, CRP overexpression increases TF and decreases TFPI expression by murine VSMCs *in vitro* and *in vivo*, and increases arterial thrombosis and intimal hyperplasia after femoral artery injury (161).

Recently, Moura *et al.* (162) reported accelerated atherosclerotic plaque maturation in *apoE*^{-/-} mice lacking thrombospondin-1, a protein implicated in various inflammatory processes (163). The authors suggested that defective thrombospondin-1-mediated phagocytosis enhances plaque necrotic core formation and accelerates inflammation and macrophage-induced elastin degradation by MMPs, thus accelerating plaque maturation and vessel wall degeneration.

6. MOUSE MODELS OF ATHEROTHROMBOSIS AND METABOLIC SYNDROME

Several animal models featuring MetS/IR and accelerated atherosclerosis have been generated in recent years by means of three main strategies (164, 165): 1) induction of obesity, IR and atherosclerosis with 'diabetogenic' or 'atherogenic' diets in susceptible mouse strains, 2) analysis of mice carrying naturally occurring mutations that produce obesity and diabetes (*Lep^{ob/ob}* and *Lep^{db/db}*) in combination with additional genetic alterations, and 3) generation of genetically-modified mice affecting genes related to glucose homeostasis and beta-cell function, in combination with diets and/or additional genetic alterations.

Relevant functional links between the MetS/IR and the acceleration of atherosclerosis have been obtained from the manipulation of *Inrs* and *Irs*, two key genes in the insulin-signaling pathway. Mice with total ablation of *Irs2* superimposed on the absence of *apoE* (*apoE*^{-/-}*Irs2*^{-/-} mice) exhibit a MetS/IR phenotype featuring glucose intolerance, hyperinsulinemia and enhanced atherosclerosis compared to similarly hypercholesterolemic *apoE*^{-/-} counterparts with intact *Irs2* (166, 167). Doubly-deficient *apoE*^{-/-}*Irs2*^{-/-} mice reveal a positive correlation between atherosclerotic burden and circulating insulin levels (167), a finding also observed in *Lep^{ob/ob}LDLr^{-/-}* and *Lep^{ob/ob}apoE^{-/-}* mice, two additional models of obesity-induced hyperlipidemia/IR/MetS and accelerated atherosclerosis

(168). Notably, accelerated atherosclerosis associated to MetS-like manifestations (e.g., glucose intolerance and mild hyperinsulinemia) has also been found in fat-fed *apoE*^{-/-}*Irs2*^{+/-} mice with only one allele of *Irs2* inactivated (169). By analyzing aortic tissue and primary VSMCs and macrophages from these mice, as well as circulating leukocytes from MetS patients with and without IR, we have recently reported that enhanced levels of MCP1 resulting from reduced IRS2 expression and accompanying defects in Akt2 and Ras/Erk1/2 signaling pathways may contribute to accelerated atherosclerosis in MetS states (169). Of note, atherosclerosis burden is similar in *apoE*^{-/-} and *apoE*^{-/-}*Irs2*^{+/-} mice fed control chow (169), indicating that reduced *Irs2* expression accelerates atherosclerosis only when combined with severe hypercholesterolemia, a frequent trait of the MetS. IR combined with severe hypercholesterolemia is also associated with severe atherosclerosis in fat-fed mice with liver-specific deletion of *Inrs* (166). Recently, Lloyd *et al.* have characterized two novel models exhibiting the phenotypes of the MetS (e.g., obesity, hyperinsulinemia, hyperlipidemia, hypertension, and atherosclerosis) by crossing *apoB48^{-/-}Lep^{ob/ob}* mice with either *apoE*^{-/-} or *Ldlr^{-/-}* mice (170).

Studies of macrophage-specific inactivation of the insulin-signaling pathway have revealed a potential mechanism causing enhanced atherosclerosis in the MetS, as transplantation of *Inrs*^{-/-} bone-marrow into irradiated *LDLr*^{-/-} mice aggravates atherosclerosis coincident with increased lipid uptake through the upregulation of CD36 and SRA (171). Consistent with this, studies in mice (172) and humans (173, 174) have linked defective insulin signaling to increased foam-cell formation through CD36 receptor enhanced expression, and murine *apoE*^{-/-}*Irs2*^{+/-} macrophages exhibit higher expression of SRA and CD36 and increased uptake of acetylated LDL compared to *apoE*^{-/-} controls with intact *Irs2* (169).

Although the aforementioned mouse models have provided new insight into the mechanisms of MetS-accelerated atherosclerosis, the occurrence of atherosclerotic acute events, like myocardial infarction, plaque rupture and thrombosis, have not been reported in these animal models. The triple *n/i/eNOS*-deficient mouse (see section 3.2.) maybe an appropriate model to study atherothrombosis in the MetS as these animals display the syndrome and severe coronary arteriosclerosis and myocardial infarction (61).

7. CONCLUSIONS AND PERSPECTIVES

Clinical and epidemiological studies have conclusively established a correlation between MetS and increased risk of arterial thrombosis and associated myocardial infarction and stroke. It has been well established that an increase in endothelial dysfunction, hypercoagulability and hypofibrinolysis produced by a dysbalance of coagulation factors, enhanced platelet reactivity and increased plaque vulnerability play a major role in the prothrombotic state induced by MetS, although understanding the precise mechanisms underlying this association requires further research.

In recent years, mouse models of atherothrombosis are being generated mainly through genetic manipulation of factors involved in the coagulation and fibrinolysis pathways. Studies with these animal models and primary cells derived from them are shedding light into the molecular mechanisms governing arterial thrombosis. Additionally, by crossing these animals with available mouse models of atherosclerosis and MetS, we are improving our knowledge into the mechanisms by which the MetS augments the risk of thrombosis and acute ischemic events. Special mention deserves the triple *n/i/eNOS*-deficient mice which develop a phenotype similar to the MetS in humans, including visceral obesity, hypertension, hypertriglyceridemia and impaired glucose tolerance, leading to severe coronary arteriosclerosis, thrombosis and myocardial infarction. While animal models pose obvious limitations, we expect that the study of genetically-modified mice will help understand the molecular mechanisms underlying MetS-induced thrombosis in humans, thus facilitating the development of novel diagnostic tools for the identification of the vulnerable plaque and therapeutic strategies for the treatment of patients at high risk of thrombosis and acute ischemic episodes.

8. ACKNOWLEDGEMENTS

We thank María J. Andrés-Manzano for help preparing the figure. Work in the authors' laboratories is supported by grants from the Spanish Ministry of Science and Innovation and the European Regional Development Fund (SAF2007-62110), Instituto de Salud Carlos III (RECAVA grants RD06/0014/0004 and RD06/0014/0021), Generalitat Valenciana (GV/2007/164), Fundación Ramón Areces, Fina Biotech S.L., and Universidad de Talca (PIFRECV, Research Program of Cardiovascular Disease Risk).

9. REFERENCES

1. Moebs, S. & A. Stang: The metabolic syndrome -- a controversial diagnostic concept. *Herz* 32, 529-40 (2007)
2. Grundy, S. M.: Metabolic Syndrome Pandemic. *Arterioscler Thromb Vasc Biol* 28, 629-36 (2008)
3. Grundy, S. M.: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. *J Am Coll Cardiol* 47, 1093-100 (2006)
4. Alexander, C. M., P. B. Landsman, S. M. Teutsch & S. M. Haffner: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. *Diabetes* 52, 1210-4 (2003)
5. Lottenberg, S. A., A. Glezer & L. A. Turatti: Metabolic syndrome: identifying the risk factors. *J Pediatr (Rio J)* 83, S204-8 (2007)
6. Beckman, J. A., M. A. Creager & P. Libby: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. *Jama* 287, 2570-81 (2002)

7. Moreno, P. R. & V. Fuster: New aspects in the pathogenesis of diabetic atherothrombosis. *J Am Coll Cardiol* 44, 2293-300 (2004)
8. Juhan-Vague, I., M. C. Alessi & P. Vague: Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. *Diabetologia* 34, 457-62 (1991)
9. Hulthe, J., L. Bokemark, J. Wikstrand & B. Fagerberg: The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. *Arterioscler Thromb Vasc Biol* 20, 2140-7 (2000)
10. Sakkinen, P. A., P. Wahl, M. Cushman, M. R. Lewis & R. P. Tracy: Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. *Am J Epidemiol* 152, 897-907 (2000)
11. Akira, S. & T. Kishimoto: IL-6 and NF-IL6 in acute-phase response and viral infection. *Immunol Rev* 127, 25-50 (1992)
12. Akira, S., H. Isshiki, T. Nakajima, S. Kinoshita, Y. Nishio, S. Natsuka & T. Kishimoto: Regulation of expression of the interleukin 6 gene: structure and function of the transcription factor NF-IL6. *Ciba Found Symp* 167, 47-62; discussion 62-7 (1992)
13. Mackman, N.: Role of tissue factor in hemostasis, thrombosis, and vascular development. *Arterioscler Thromb Vasc Biol* 24, 1015-22 (2004)
14. Kim, J. A., M. Montagnani, K. K. Koh & M. J. Quon: Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. *Circulation* 113, 1888-904 (2006)
15. Michiels, C.: Endothelial cell functions. *J Cell Physiol* 196, 430-43 (2003)
16. Verma, S., P. E. Szmitko & T. J. Anderson: Endothelial function: ready for prime time? *Can J Cardiol* 20, 1335-9 (2004)
17. Rubio, A. R. & M. A. Morales-Segura: Nitric oxide, an iceberg in cardiovascular physiology: far beyond vessel tone control. *Arch Med Res* 35, 1-11 (2004)
18. Hsueh, W. A. & M. J. Quinones: Role of endothelial dysfunction in insulin resistance. *Am J Cardiol* 92, 10J-17J (2003)
19. Diamant, M. & M. E. Tushuizen: The metabolic syndrome and endothelial dysfunction: common highway to type 2 diabetes and CVD. *Curr Diab Rep* 6, 279-86 (2006)
20. Ruderman, N. B., J. M. Cacicedo, S. Itani, N. Yagihashi, A. K. Saha, J. M. Ye, K. Chen, M. Zou, D. Carling, G. Boden, R. A. Cohen, J. Keaney, E. W. Kraegen

& Y. Ido: Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. *Biochem Soc Trans* 31, 202-6 (2003)

21. Kuroki, T., K. Isshiki & G. L. King: Oxidative stress: the lead or supporting actor in the pathogenesis of diabetic complications. *J Am Soc Nephrol* 14, S216-20 (2003)

22. Fernandez-Real, J. M. & W. Ricart: Insulin resistance and chronic cardiovascular inflammatory syndrome. *Endocr Rev* 24, 278-301 (2003)

23. Singleton, J. R., A. G. Smith, J. W. Russell & E. L. Feldman: Microvascular complications of impaired glucose tolerance. *Diabetes* 52, 2867-73 (2003)

24. Avogaro, A., G. P. Fadini, A. Gallo, E. Pagnin & S. de Kreutzenberg: Endothelial dysfunction in type 2 diabetes mellitus. *Nutr Metab Cardiovasc Dis* 16 Suppl 1, S39-45 (2006)

25. Wheatcroft, S. B., I. L. Williams, A. M. Shah & M. T. Kearney: Pathophysiological implications of insulin resistance on vascular endothelial function. *Diabet Med* 20, 255-68 (2003)

26. King, G. L. & M. R. Loeken: Hyperglycemia-induced oxidative stress in diabetic complications. *Histochem Cell Biol* 122, 333-8 (2004)

27. Balletshofer, B. M., K. Rittig, M. D. Enderle, A. Volk, E. Maerker, S. Jacob, S. Matthaei, K. Rett & H. U. Haring: Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. *Circulation* 101, 1780-4 (2000)

28. Caballero, A. E., S. Arora, R. Saouaf, S. C. Lim, P. Smakowski, J. Y. Park, G. L. King, F. W. LoGerfo, E. S. Horton & A. Veves: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. *Diabetes* 48, 1856-62 (1999)

29. Williams, I. L., P. J. Chowienczyk, S. B. Wheatcroft, A. G. Patel, R. A. Sherwood, A. Momin, A. M. Shah & M. T. Kearney: Endothelial function and weight loss in obese humans. *Obes Surg* 15, 1055-60 (2005)

30. Wheatcroft, S. B., A. M. Shah, J. M. Li, E. Duncan, B. T. Noronha, P. A. Crossey & M. T. Kearney: Preserved glucoregulation but attenuation of the vascular actions of insulin in mice heterozygous for knockout of the insulin receptor. *Diabetes* 53, 2645-52 (2004)

31. Noronha, B. T., J. M. Li, S. B. Wheatcroft, A. M. Shah & M. T. Kearney: Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. *Diabetes* 54, 1082-9 (2005)

32. Jiang, Z. Y., Y. W. Lin, A. Clemont, E. P. Feener, K. D. Hein, M. Igarashi, T. Yamauchi, M. F. White & G. L.

King: Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. *J Clin Invest* 104, 447-57 (1999)

33. Cusi, K., K. Maezono, A. Osman, M. Pendergrass, M. E. Patti, T. Pratipanawatr, R. A. DeFronzo, C. R. Kahn & L. J. Mandarino: Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. *J Clin Invest* 105, 311-20 (2000)

34. Yamagishi, S., H. Fujimori, H. Yonekura, Y. Yamamoto & H. Yamamoto: Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. *Diabetologia* 41, 1435-41 (1998)

35. Quehenberger, P., A. Bierhaus, P. Fasching, C. Muellner, M. Klevesath, M. Hong, G. Stier, M. Sattler, E. Schleicher, W. Speiser & P. P. Nawroth: Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. *Diabetes* 49, 1561-70 (2000)

36. Bucala, R., K. J. Tracey & A. Cerami: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. *J Clin Invest* 87, 432-8 (1991)

37. Chakravarthy, U., R. G. Hayes, A. W. Stitt, E. McAuley & D. B. Archer: Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. *Diabetes* 47, 945-52 (1998)

38. Xu, B., R. Chibber, D. Ruggiero, E. Kohner, J. Ritter & A. Ferro: Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. *Faseb J* 17, 1289-91 (2003)

39. Rojas, A., S. Romay, D. Gonzalez, B. Herrera, R. Delgado & K. Otero: Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. *Circ Res* 86, E50-4 (2000)

40. Berg, A. H. & P. E. Scherer: Adipose tissue, inflammation, and cardiovascular disease. *Circ Res* 96, 939-49 (2005)

41. Dentali, F., E. Romualdi & W. Ageno: The metabolic syndrome and the risk of thrombosis. *Haematologica* 92, 297-9 (2007)

42. Ouchi, N., S. Kihara, Y. Arita, K. Maeda, H. Kuriyama, Y. Okamoto, K. Hotta, M. Nishida, M. Takahashi, T. Nakamura, S. Yamashita, T. Funahashi & Y. Matsuzawa: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. *Circulation* 100, 2473-6 (1999)

43. Hotta, K., T. Funahashi, Y. Arita, M. Takahashi, M. Matsuda, Y. Okamoto, H. Iwahashi, H. Kuriyama, N. Ouchi, K. Maeda, M. Nishida, S. Kihara, N. Sakai, T.

- Nakajima, K. Hasegawa, M. Muraguchi, Y. Ohmoto, T. Nakamura, S. Yamashita, T. Hanafusa & Y. Matsuzawa: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol* 20, 1595-9 (2000)
44. Tan, K. C., A. Xu, W. S. Chow, M. C. Lam, V. H. Ai, S. C. Tam & K. S. Lam: Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. *J Clin Endocrinol Metab* 89, 765-9 (2004)
45. Ouchi, N., M. Ohishi, S. Kihara, T. Funahashi, T. Nakamura, H. Nagaretani, M. Kumada, K. Ohashi, Y. Okamoto, H. Nishizawa, K. Kishida, N. Maeda, A. Nagasawa, H. Kobayashi, H. Hiraoka, N. Komai, M. Kaibe, H. Rakugi, T. Ogihara & Y. Matsuzawa: Association of hypoadiponectinemia with impaired vasoreactivity. *Hypertension* 42, 231-4 (2003)
46. Shimabukuro, M., N. Higa, T. Asahi, Y. Oshiro, N. Takasu, T. Tagawa, S. Ueda, I. Shimomura, T. Funahashi & Y. Matsuzawa: Hypoadiponectinemia is closely linked to endothelial dysfunction in man. *J Clin Endocrinol Metab* 88, 3236-40 (2003)
47. Fernandez-Real, J. M., A. Castro, G. Vazquez, R. Casamitjana, A. Lopez-Bermejo, G. Penarroja & W. Ricart: Adiponectin is associated with vascular function independent of insulin sensitivity. *Diabetes Care* 27, 739-45 (2004)
48. Wang, X. L., L. Zhang, K. Youker, M. X. Zhang, J. Wang, S. A. LeMaire, J. S. Coselli & Y. H. Shen: Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. *Diabetes* 55, 2301-10 (2006)
49. Aicher, A., A. M. Zeiher & S. Dimmeler: Mobilizing endothelial progenitor cells. *Hypertension* 45, 321-5 (2005)
50. Ceradini, D. J., A. R. Kulkarni, M. J. Callaghan, O. M. Tepper, N. Bastidas, M. E. Kleinman, J. M. Capla, R. D. Galiano, J. P. Levine & G. C. Gurtner: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. *Nat Med* 10, 858-64 (2004)
51. Asahara, T., T. Murohara, A. Sullivan, M. Silver, R. van der Zee, T. Li, B. Witzendichler, G. Schatteman & J. M. Isner: Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 275, 964-7 (1997)
52. Rafii, S. & D. Lyden: Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. *Nat Med* 9, 702-12 (2003)
53. Werner, N., S. Kosiol, T. Schiegl, P. Ahlers, K. Walenta, A. Link, M. Bohm & G. Nickenig: Circulating endothelial progenitor cells and cardiovascular outcomes. *N Engl J Med* 353, 999-1007 (2005)
54. Choy, J. C., D. J. Granville, D. W. Hunt & B. M. McManus: Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. *J Mol Cell Cardiol* 33, 1673-90 (2001)
55. Hill, J. M., G. Zalos, J. P. Halcox, W. H. Schenke, M. A. Waclawiw, A. A. Quyyumi & T. Finkel: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med* 348, 593-600 (2003)
56. Vasa, M., S. Fichtlscherer, A. Aicher, K. Adler, C. Urbich, H. Martin, A. M. Zeiher & S. Dimmeler: Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res* 89, E1-7 (2001)
57. Nathan, C. & Q. W. Xie: Nitric oxide synthases: roles, tolls, and controls. *Cell* 78, 915-8 (1994)
58. Mashimo, H. & R. K. Goyal: Lessons from genetically engineered animal models. IV. Nitric oxide synthase gene knockout mice. *Am J Physiol* 277, G745-50 (1999)
59. Huang, P. L.: Mouse models of nitric oxide synthase deficiency. *J Am Soc Nephrol* 11 Suppl 16, S120-3 (2000)
60. Morishita, T., M. Tsutsui, H. Shimokawa, K. Sabanai, H. Tasaki, O. Suda, S. Nakata, A. Tanimoto, K. Y. Wang, Y. Ueta, Y. Sasaguri, Y. Nakashima & N. Yanagihara: Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. *Proc Natl Acad Sci U S A* 102, 10616-21 (2005)
61. Nakata, S., M. Tsutsui, H. Shimokawa, O. Suda, T. Morishita, K. Shibata, Y. Yatera, K. Sabanai, A. Tanimoto, M. Nagasaki, H. Tasaki, Y. Sasaguri, Y. Nakashima, Y. Otsuji & N. Yanagihara: Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. *Circulation* 117, 2211-23 (2008)
62. Duncan, E. R., S. J. Walker, V. A. Ezzat, S. B. Wheatcroft, J. M. Li, A. M. Shah & M. T. Kearney: Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. *Am J Physiol Endocrinol Metab* 293, E1311-9 (2007)
63. Kim, F., M. Pham, I. Luttrell, D. D. Bannerman, J. Tupper, J. Thaler, T. R. Hawn, E. W. Raines & M. W. Schwartz: Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. *Circ Res* 100, 1589-96 (2007)
64. Palomo, I., M. Alarcon, R. Moore-Carrasco & J. M. Argiles: Hemostasis alterations in metabolic syndrome. *Int J Mol Med* 18, 969-74 (2006)
65. Binder, B. R., G. Christ, F. Gruber, N. Grubic, P. Hufnagl, M. Krebs, J. Mihaly & G. W. Prager: Plasminogen activator inhibitor 1: physiological and pathophysiological roles. *News Physiol Sci* 17, 56-61 (2002)
66. Hamsten, A., U. de Faire, G. Walldius, G. Dahlen, A. Szamosi, C. Landou, M. Blomback & B. Wiman:

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. *Lancet* 2, 3-9 (1987)

67. Palomo, I., C. Gutiérrez, M. Alarcón, J. Jaramillo, F. Segovia, E. Leiva, V. Mujica, G. Icaza, N. Díaz & R. Moore-Carrasco: Increased Concentration of Plasminogen Activator Inhibitor-1 and Fibrinogen in Individuals with Metabolic Syndrome. *Molecular Medicine Reports* 2, 253-257 (2009)

68. Aso, Y.: Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. *Front Biosci* 12, 2957-66 (2007)

69. Zorio, E., J. Gilabert-Estelles, F. Espana, L. A. Ramon, R. Cosin & A. Estelles: Fibrinolysis: the key to new pathogenetic mechanisms. *Curr Med Chem* 15, 923-9 (2008)

70. Lansbury, A. J., P. J. Grant & A. J. Catto: Atherothrombotic risk factors in subjects with a family history of stroke. *Cerebrovasc Dis* 14, 153-60 (2002)

71. Ginsberg, H. N.: Insulin resistance and cardiovascular disease. *J Clin Invest* 106, 453-8 (2000)

72. Mills, J. D., M. W. Mansfield & P. J. Grant: Factor XIII-circulating levels and the Val34Leu polymorphism in the healthy male relatives of patients with severe coronary artery disease. *Thromb Haemost* 87, 409-14 (2002)

73. Lin, C. P., W. T. Lin, H. B. Leu, T. C. Wu & J. W. Chen: Differential mononuclear cell activity and endothelial inflammation in coronary artery disease and cardiac syndrome X. *Int J Cardiol* 89, 53-62 (2003)

74. Barry, O. P. & G. A. FitzGerald: Mechanisms of cellular activation by platelet microparticles. *Thromb Haemost* 82, 794-800 (1999)

75. Giesen, P. L., U. Rauch, B. Bohrmann, D. Kling, M. Roque, J. T. Fallon, J. J. Badimon, J. Himber, M. A. Riederer & Y. Nemerson: Blood-borne tissue factor: another view of thrombosis. *Proc Natl Acad Sci U S A* 96, 2311-5 (1999)

76. Viles-Gonzalez, J. F., S. X. Anand, M. U. Zafar, V. Fuster & J. J. Badimon: Tissue factor coagulation pathway: a new therapeutic target in atherothrombosis. *J Cardiovasc Pharmacol* 43, 669-76 (2004)

77. Atsuchi, N., T. Nishida, K. Marutsuka, Y. Asada, Y. Kamikubo, A. Takeshita & H. Ueno: Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. *Circulation* 103, 570-5 (2001)

78. Sajadi, S., M. D. Ezekowitz, A. Dhond & P. Netrebko: Tissue factor pathway inhibitors as a novel approach to antithrombotic therapy. *Drug News Perspect* 16, 363-9 (2003)

79. Morange, P. E., J. F. Renucci, M. A. Charles, M. F. Aillaud, F. Giraud, M. Grimaux & I. Juhan-Vague: Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. *Thromb Haemost* 85, 999-1003 (2001)

80. Kopp, C. W., H. P. Kopp, S. Steiner, S. Kriwanek, K. Krzyzanowska, A. Bartok, R. Roka, E. Minar & G. Schernthaner: Weight loss reduces tissue factor in morbidly obese patients. *Obes Res* 11, 950-6 (2003)

81. Miller, G. J.: Lipoproteins and thrombosis: effects of lipid lowering. *Curr Opin Lipidol* 6, 38-42 (1995)

82. Meigs, J. B., M. A. Mittleman, D. M. Nathan, G. H. Tofler, D. E. Singer, P. M. Murphy-Sheehy, I. Lipinska, R. B. D'Agostino & P. W. Wilson: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. *Jama* 283, 221-8 (2000)

83. Kohler, H. P. & P. J. Grant: Plasminogen-activator inhibitor type 1 and coronary artery disease. *N Engl J Med* 342, 1792-801 (2000)

84. Hamsten, A., B. Wiman, U. de Faire & M. Blomback: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. *N Engl J Med* 313, 1557-63 (1985)

85. Ridker, P. M., D. E. Vaughan, M. J. Stampfer, J. E. Manson & C. H. Hennekens: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. *Lancet* 341, 1165-8 (1993)

86. Aznar, J., A. Estelles, G. Tormo, P. Sapena, V. Tormo, S. Blanch & F. Espana: Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. *Br Heart J* 59, 535-41 (1988)

87. Pandolfi, A., D. Cetrullo, R. Polishuck, M. M. Alberta, A. Calafiore, G. Pellegrini, E. Vitacolonna, F. Capani & A. Consoli: Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. *Arterioscler Thromb Vasc Biol* 21, 1378-82 (2001)

88. Vaughan, D. E.: PAI-1 and atherothrombosis. *J Thromb Haemost* 3, 1879-83 (2005)

89. Festa, A., R. D'Agostino, Jr., R. P. Tracy & S. M. Haffner: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. *Diabetes* 51, 1131-7 (2002)

90. Beltowski, J.: Adiponectin and resistin--new hormones of white adipose tissue. *Med Sci Monit* 9, RA55-61 (2003)

91. Eriksson, P., S. Reynisdottir, F. Lonnqvist, V. Stemme, A. Hamsten & P. Arner: Adipose tissue

secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. *Diabetologia* 41, 65-71 (1998)

92. Skurk, T. & H. Hauner: Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. *Int J Obes Relat Metab Disord* 28, 1357-64 (2004)

93. Alessi, M. C., M. Poggi & I. Juhan-Vague: Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. *Curr Opin Lipidol* 18, 240-5 (2007)

94. Muscelli, E., S. Camastra, C. Catalano, A. Q. Galvan, D. Ciociaro, S. Baldi & E. Ferrannini: Metabolic and cardiovascular assessment in moderate obesity: effect of weight loss. *J Clin Endocrinol Metab* 82, 2937-43 (1997)

95. Estelles, A., J. Aznar, G. Tormo, P. Sapena, V. Tormo & F. Espana: Influence of a rehabilitation sports programme on the fibrinolytic activity of patients after myocardial infarction. *Thromb Res* 55, 203-12 (1989)

96. Sola, E., A. Vaya, F. Espana, R. Castello, L. A. Ramon, A. Hernandez-Mijares, V. Vicente & A. Estelles: Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism. *Thromb Res* 122, 320-7 (2008)

97. Godsland, I. F., D. Crook, A. J. Proudler & J. C. Stevenson: Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. *J Clin Endocrinol Metab* 90, 190-7 (2005)

98. Aubert, H., C. Frere, M. F. Aillaud, P. E. Morange, I. Juhan-Vague & M. C. Alessi: Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. *J Thromb Haemost* 1, 791-7 (2003)

99. Griffin, J. H., K. Kojima, C. L. Banka, L. K. Curtiss & J. A. Fernandez: High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. *J Clin Invest* 103, 219-27 (1999)

100. Zorio, E., S. Navarro, P. Medina, A. Estelles, A. Osa, J. Rueda, P. Cubillo, J. Aznar & F. Espana: Circulating activated protein C is reduced in young survivors of myocardial infarction and inversely correlates with the severity of coronary lesions. *J Thromb Haemost* 4, 1530-6 (2006)

101. Lopes, C., C. Dina, E. Durand & P. Froguel: PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. *Diabetologia* 46, 1284-90 (2003)

102. Ruggeri, Z. M. & G. L. Mendolicchio: Adhesion mechanisms in platelet function. *Circ Res* 100, 1673-85 (2007)

103. Langer, H. F. & M. Gawaz: Platelet-vessel wall interactions in atherosclerotic disease. *Thromb Haemost* 99, 480-6 (2008)

104. Kabbani, S. S., M. W. Watkins, T. Ashikaga, E. F. Terrien, B. E. Sobel & D. J. Schneider: Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. *Am J Cardiol* 91, 876-8 (2003)

105. Trip, M. D., V. M. Cats, F. J. van Capelle & J. Vreeken: Platelet hyperreactivity and prognosis in survivors of myocardial infarction. *N Engl J Med* 322, 1549-54 (1990)

106. Davi, G. & C. Patrono: Platelet activation and atherothrombosis. *N Engl J Med* 357, 2482-94 (2007)

107. Vericel, E., C. Januel, M. Carreras, P. Moulin & M. Lagarde: Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. *Diabetes* 53, 1046-51 (2004)

108. Serebruany, V. L., A. Malinin, S. Ong & D. Atar: Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. *J Thromb Thrombolysis* 25, 207-13 (2008)

109. Nomura, S.: Platelet activation marker. *Rinsho Byori* 51, 1096-101 (2003)

110. Geng, J. G., M. P. Bevilacqua, K. L. Moore, T. M. McIntyre, S. M. Prescott, J. M. Kim, G. A. Bliss, G. A. Zimmerman & R. P. McEver: Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. *Nature* 343, 757-60 (1990)

111. Wu, Y., Z. Zhou & M. E. Meyerhoff: *In vitro* platelet adhesion on polymeric surfaces with varying fluxes of continuous nitric oxide release. *J Biomed Mater Res A* 81, 956-63 (2007)

112. Khandoga, A., P. Biberthaler, K. Messmer & F. Krombach: Platelet-endothelial cell interactions during hepatic ischemia-reperfusion *in vivo*: a systematic analysis. *Microvasc Res* 65, 71-7 (2003)

113. Elbatarny, H. S., S. J. Netherton, J. D. Ovens, A. V. Ferguson & D. H. Maurice: Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. *Eur J Pharmacol* 558, 7-13 (2007)

114. Panes, O., V. Matus, C. G. Saez, T. Quiroga, J. Pereira & D. Mezzano: Human platelets synthesize and express functional tissue factor. *Blood* 109, 5242-50 (2007)

115. Nomura, S., M. Suzuki, K. Katsura, G. L. Xie, Y. Miyazaki, T. Miyake, H. Kido, H. Kagawa & S. Fukuhara: Platelet-derived microparticles may influence the

development of atherosclerosis in diabetes mellitus. *Atherosclerosis* 116, 235-40 (1995)

116. Merten, M., R. Pakala, P. Thiagarajan & C. R. Benedict: Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism. *Circulation* 99, 2577-82 (1999)

117. Gawaz, M., F. J. Neumann, I. Ott, A. Schiessler & A. Schomig: Platelet function in acute myocardial infarction treated with direct angioplasty. *Circulation* 93, 229-37 (1996)

118. Mause, S. F., P. von Hundelshausen, A. Zerneck, R. Koenen & C. Weber: Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. *Arterioscler Thromb Vasc Biol* 25, 1512-8 (2005)

119. Boulanger, C. M., A. Scoazec, T. Ebrahimian, P. Henry, E. Mathieu, A. Tedgui & Z. Mallat: Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. *Circulation* 104, 2649-52 (2001)

120. Podrez, E. A., T. V. Byzova, M. Febbraio, R. G. Salomon, Y. Ma, M. Valiyaveetil, E. Poliakov, M. Sun, P. J. Finton, B. R. Curtis, J. Chen, R. Zhang, R. L. Silverstein & S. L. Hazen: Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. *Nat Med* 13, 1086-95 (2007)

121. Huo, Y., A. Schober, S. B. Forlow, D. F. Smith, M. C. Hyman, S. Jung, D. R. Littman, C. Weber & K. Ley: Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. *Nat Med* 9, 61-7 (2003)

122. Blann, A. D., S. K. Nadar & G. Y. Lip: The adhesion molecule P-selectin and cardiovascular disease. *Eur Heart J* 24, 2166-79 (2003)

123. Gawaz, M., H. Langer & A. E. May: Platelets in inflammation and atherogenesis. *J Clin Invest* 115, 3378-84 (2005)

124. Gawaz, M., K. Brand, T. Dickfeld, G. Pogatsa-Murray, S. Page, C. Bogner, W. Koch, A. Schomig & F. Neumann: Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. *Atherosclerosis* 148, 75-85 (2000)

125. Hawrylowicz, C. M., G. L. Howells & M. Feldmann: Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. *J Exp Med* 174, 785-90 (1991)

126. Kaplanski, G., R. Porat, K. Aiura, J. K. Erban, J. A. Gelfand & C. A. Dinarello: Activated platelets induce endothelial secretion of interleukin-8 *in vitro* via an interleukin-1-mediated event. *Blood* 81, 2492-5 (1993)

127. Scheuerer, B., M. Ernst, I. Durrbaum-Landmann, J. Fleischer, E. Grage-Griebenow, E. Brandt, H. D. Flad & F. Petersen: The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. *Blood* 95, 1158-66 (2000)

128. Nassar, T., B. S. Sachais, S. Akkawi, M. A. Kowalska, K. Bdeir, E. Leitersdorf, E. Hiss, L. Ziporen, M. Aviram, D. Cines, M. Poncz & A. A. Higazi: Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. *J Biol Chem* 278, 6187-93 (2003)

129. von Hundelshausen, P., R. R. Koenen, M. Sack, S. F. Mause, W. Adriaens, A. E. Proudfoot, T. M. Hackeng & C. Weber: Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. *Blood* 105, 924-30 (2005)

130. Izaguirre Avila, R., A. de la Pena, H. Gonzalez Pacheco, A. Ramirez Gutierrez, H. Gonzalez Valdez, A. Quiroz, E. Cortina, M. Huerta & E. Lupi: Efficacy of clopidogrel as ADP-dependent platelet aggregation inhibitor. Study on individuals with coronary artery disease. *Arch Inst Cardiol Mex* 70, 472-80 (2000)

131. Andres, V.: Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential. *Cardiovasc Res* 63, 11-21 (2004)

132. Castro, C., A. Diez-Juan, M. J. Cortes & V. Andres: Distinct regulation of mitogen-activated protein kinases and p27Kip1 in smooth muscle cells from different vascular beds. A potential role in establishing regional phenotypic variance. *J Biol Chem* 278, 4482-90 (2003)

133. Diez-Juan, A. & V. Andres: Coordinate control of proliferation and migration by the p27Kip1/cyclin-dependent kinase/retinoblastoma pathway in vascular smooth muscle cells and fibroblasts. *Circ Res* 92, 402-10 (2003)

134. Diez-Juan, A. & V. Andres: The growth suppressor p27(Kip1) protects against diet-induced atherosclerosis. *Faseb J* 15, 1989-95 (2001)

135. Diez-Juan, A., P. Perez, M. Aracil, D. Sancho, A. Bernad, F. Sanchez-Madrid & V. Andres: Selective inactivation of p27(Kip1) in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis. *Blood* 103, 158-61 (2004)

136. Massberg, S., F. Vogt, T. Dickfeld, K. Brand, S. Page & M. Gawaz: Activated platelets trigger an inflammatory response and enhance migration of aortic smooth muscle cells. *Thromb Res* 110, 187-94 (2003)

137. Virmani, R., A. P. Burke, A. Farb & F. D. Kolodgie: Pathology of the vulnerable plaque. *J Am Coll Cardiol* 47, C13-8 (2006)

138. Heeneman, S., E. Lutgens, K. B. Schapira, M. J. Daemen & E. A. Biessen: Control of atherosclerotic plaque

vulnerability: insights from transgenic mice. *Front Biosci* 13, 6289-313 (2008)

139. Jackson, C. L.: Is there life after plaque rupture? *Biochem Soc Trans* 35, 887-9 (2007)

140. Jackson, C. L.: Defining and defending murine models of plaque rupture. *Arterioscler Thromb Vasc Biol* 27, 973-7 (2007)

141. Naghavi, M., P. Libby, E. Falk, S. W. Casscells, S. Litovsky, J. Rumberger, J. J. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, Z. Fayad, P. H. Stone, S. Waxman, P. Raggi, M. Madjid, A. Zarrabi, A. Burke, C. Yuan, P. J. Fitzgerald, D. S. Siscovick, C. L. de Korte, M. Aikawa, K. E. Juhani Airaksinen, G. Assmann, C. R. Becker, J. H. Chesebro, A. Farb, Z. S. Galis, C. Jackson, I. K. Jang, W. Koenig, R. A. Lodder, K. March, J. Demirovic, M. Navab, S. G. Priori, M. D. Reikhter, R. Bahr, S. M. Grundy, R. Mehran, A. Colombo, E. Boerwinkle, C. Ballantyne, W. Insull, Jr., R. S. Schwartz, R. Vogel, P. W. Serruys, G. K. Hansson, D. P. Faxon, S. Kaul, H. Drexler, P. Greenland, J. E. Muller, R. Virmani, P. M. Ridker, D. P. Zipes, P. K. Shah & J. T. Willerson: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. *Circulation* 108, 1664-72 (2003)

142. Zadelaar, S., R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen & T. Kooistra: Mouse models for atherosclerosis and pharmaceutical modifiers. *Arterioscler Thromb Vasc Biol* 27, 1706-21 (2007)

143. Schwartz, S. M., Z. S. Galis, M. E. Rosenfeld & E. Falk: Plaque rupture in humans and mice. *Arterioscler Thromb Vasc Biol* 27, 705-13 (2007)

144. Jackson, C. L., Benbow, U., Galley, D.J., Karanam, S.: Models of plaque rupture. *Drug Discovery Today: Disease Models Cardiovascular disease* 4, 171-175 (2007)

145. Westrick, R. J., M. E. Winn & D. T. Eitzman: Murine models of vascular thrombosis (Eitzman series). *Arterioscler Thromb Vasc Biol* 27, 2079-93 (2007)

146. Sachs, U. J. & B. Nieswandt: *In vivo* thrombus formation in murine models. *Circ Res* 100, 979-91 (2007)

147. Braun, A., B. L. Trigatti, M. J. Post, K. Sato, M. Simons, J. M. Edelberg, R. D. Rosenberg, M. Schrenzel & M. Krieger: Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. *Circ Res* 90, 270-6 (2002)

148. Sasaki, T., M. Kuzuya, K. Nakamura, X. W. Cheng, T. Shibata, K. Sato & A. Iguchi: A simple method of plaque rupture induction in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol* 26, 1304-9 (2006)

149. Johnson, J., K. Carson, H. Williams, S. Karanam, A. Newby, G. Angelini, S. George & C. Jackson: Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. *Circulation* 111, 1422-30 (2005)

150. von der Thusen, J. H., B. J. van Vlijmen, R. C. Hoeber, M. M. Kockx, L. M. Havekes, T. J. van Berkel & E. A. Biessen: Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. *Circulation* 105, 2064-70 (2002)

151. Zadelaar, A. S., J. H. von der Thusen, L. S. Boesten, R. C. Hoeber, M. M. Kockx, M. A. Versnel, T. J. van Berkel, L. M. Havekes, E. A. Biessen & B. J. van Vlijmen: Increased vulnerability of pre-existing atherosclerosis in ApoE-deficient mice following adenovirus-mediated Fas ligand gene transfer. *Atherosclerosis* 183, 244-50 (2005)

152. Johnson, J. L., S. J. George, A. C. Newby & C. L. Jackson: Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. *Proc Natl Acad Sci U S A* 102, 15575-80 (2005)

153. de Nooijer, R., C. J. Verkleij, J. H. von der Thusen, J. W. Jukema, E. E. van der Wall, T. J. van Berkel, A. H. Baker & E. A. Biessen: Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. *Arterioscler Thromb Vasc Biol* 26, 340-6 (2006)

154. Eitzman, D. T., R. J. Westrick, Y. Shen, P. F. Bodary, S. Gu, S. L. Manning, S. L. Dobies & D. Ginsburg: Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice. *Circulation* 111, 1822-5 (2005)

155. Xiao, Q., M. J. Danton, D. P. Witte, M. C. Kowala, M. T. Valentine, T. H. Bugge & J. L. Degen: Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. *Proc Natl Acad Sci U S A* 94, 10335-40 (1997)

156. Eren, M., C. A. Painter, J. B. Atkinson, P. J. Declerck & D. E. Vaughan: Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. *Circulation* 106, 491-6 (2002)

157. Eitzman, D. T., R. J. Westrick, Z. Xu, J. Tyson & D. Ginsburg: Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. *Blood* 96, 4212-5 (2000)

158. Luttun, A., F. Lupu, E. Storkebaum, M. F. Hoylaerts, L. Moons, J. Crawley, F. Bono, A. R. Poole, P. Tipping, J. M. Herbert, D. Collen & P. Carmeliet: Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic

plaques in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol* 22, 499-505 (2002)

159. Westrick, R. J., P. F. Bodary, Z. Xu, Y. C. Shen, G. J. Broze & D. T. Eitzman: Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. *Circulation* 103, 3044-6 (2001)

160. Danenberg, H. D., A. J. Szalai, R. V. Swaminathan, L. Peng, Z. Chen, P. Seifert, W. P. Fay, D. I. Simon & E. R. Edelman: Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. *Circulation* 108, 512-5 (2003)

161. Wu, J., M. J. Stevenson, J. M. Brown, E. A. Grunz, T. L. Strawn & W. P. Fay: C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and *in vivo* significance. *Arterioscler Thromb Vasc Biol* 28, 698-704 (2008)

162. Moura, R., M. Tjwa, P. Vandervoort, S. Van Kerckhoven, P. Holvoet & M. F. Hoylaerts: Thrombospondin-1 deficiency accelerates atherosclerotic plaque maturation in ApoE^{-/-} mice. *Circ Res* 103, 1181-9 (2008)

163. Bornstein, P., A. Agah & T. R. Kyriakides: The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. *Int J Biochem Cell Biol* 36, 1115-25 (2004)

164. Gonzalez-Navarro, H., D. J. Burks & V. Andres: Murine models to investigate the influence of diabetic metabolism on the development of atherosclerosis and restenosis. *Front Biosci* 12, 4439-55 (2007)

165. Hsueh, W., E. D. Abel, J. L. Breslow, N. Maeda, R. C. Davis, E. A. Fisher, H. Dansky, D. A. McClain, R. McIndoe, M. K. Wassef, C. Rabadan-Diehl & I. J. Goldberg: Recipes for creating animal models of diabetic cardiovascular disease. *Circ Res* 100, 1415-27 (2007)

166. Baumgartl, J., S. Baudler, M. Scherner, V. Babaev, L. Makowski, J. Suttles, M. McDuffie, S. Fazio, C. R. Kahn, G. S. Hotamisligil, W. Krone, M. Linton & J. C. Bruning: Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis. *Cell Metab* 3, 247-56 (2006)

167. Gonzalez-Navarro, H., M. Vila-Caballer, M. F. Pastor, A. Vinue, M. F. White, D. Burks & V. Andres: Plasma insulin levels predict the development of atherosclerosis when IRS2 deficiency is combined with severe hypercholesterolemia in apolipoprotein E-null mice. *Front Biosci* 12, 2291-8 (2007)

168. Gruen, M. L., V. Saraswathi, A. M. Nuotio-Antar, M. R. Plummer, K. R. Coenen & A. H. Hasty: Plasma insulin levels predict atherosclerotic lesion burden in obese hyperlipidemic mice. *Atherosclerosis* 186, 54-64 (2006)

169. Gonzalez-Navarro, H., A. Vinue, M. Vila-Caballer, A. Fortuno, O. Beloqui, G. Zalba, D. Burks, J. Diez & V. Andres: Molecular Mechanisms of Atherosclerosis in Metabolic Syndrome: Role of Reduced IRS2-Dependent Signaling. *Arterioscler Thromb Vasc Biol* 28, 2187-2194 (2008)

170. Lloyd, D. J., J. McCormick, J. Helmering, K. W. Kim, M. Wang, P. Fordstrom, S. A. Kaufman, R. A. Lindberg & M. M. Veniant: Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48^{-/-}Lepob/ob mice devoid of ApoE or Ldlr. *Am J Physiol Endocrinol Metab* 294, E496-505 (2008)

171. Han, S., C. P. Liang, T. Devries-Seimon, M. Ranalletta, C. L. Welch, K. Collins-Fletcher, D. Accili, I. Tabas & A. R. Tall: Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. *Cell Metab* 3, 257-66 (2006)

172. Liang, C. P., S. Han, H. Okamoto, R. Carnemolla, I. Tabas, D. Accili & A. R. Tall: Increased CD36 protein as a response to defective insulin signaling in macrophages. *J Clin Invest* 113, 764-73 (2004)

173. Griffin, E., A. Re, N. Hamel, C. Fu, H. Bush, T. McCaffrey & A. S. Asch: A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. *Nat Med* 7, 840-6 (2001)

174. Sampson, M. J., I. R. Davies, S. Braschi, K. Ivory & D. A. Hughes: Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes. *Atherosclerosis* 167, 129-34 (2003)

Key Words: metabolic syndrome, endothelial dysfunction, haemostasis, thrombosis, plaque vulnerability, platelet activation, genetically-modified mice.

Send correspondence to: Herminia Gonzalez-Navarro, Laboratory of Vascular Biology, Consejo Superior de Investigaciones Científicas, Instituto de Biomedicina de Valencia, Jaime Roig, 11, 46010 - Valencia, Spain, Tel: 34-96-3391750, Fax: 34-96-3391751, E-mail: hgonzalez@ibv.csic.es

<http://www.bioscience.org/current/volS2.htm>